LogicBio® Therapeutics, Inc.

Practice Area: 
Stock Symbol: 
Case Status: 

Ademi LLP is investigating LogicBio (NASDAQ: LOGC) for possible breaches of fiduciary duty and other violations of law in its transaction with AstraZeneca.

Ademi LLP alleges LogicBio’s financial outlook and prospects are excellent and yet LogicBio holders will receive only $2.07 per share in a cash tender offer. The transaction agreement unreasonably limits competing bids for LogicBio by imposing a significant penalty if LogicBio accepts a superior bid. LogicBio insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of LogicBio’s board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for LogicBio.